Ganetespib: research and clinical development
Komal Jhaveri, Shanu Modi Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA Abstract: Under stressful conditions, the heat shock protein 90 (HSP90) molecular chaperone protects cellular proteins (client proteins) from degradation via the ubi...
Main Authors: | Jhaveri K, Modi S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-07-01
|
Series: | OncoTargets and Therapy |
Online Access: | http://www.dovepress.com/ganetespib-research-and-clinical-development-peer-reviewed-article-OTT |
Similar Items
-
Activity of the heat shock protein 90 inhibitor ganetespib in melanoma.
by: Xinqi Wu, et al.
Published: (2013-01-01) -
The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells
by: Roberto Gomez-Casal, et al.
Published: (2015-05-01) -
Effects of Hsp90 Inhibitor Ganetespib on Inhibition of Azole-Resistant Candida albicans
by: Rui Yuan, et al.
Published: (2021-05-01) -
A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer
by: Komal Jhaveri, et al.
Published: (2017-08-01) -
The HSP-RTK-Akt axis mediates acquired resistance to Ganetespib in HER2-positive breast cancer
by: Christopher E. Eyermann, et al.
Published: (2021-01-01)